MicroA
MicroA is revolutionising respiratory care with its next-generation, broad-spectrum anti-inflammatory and antiviral platform technology. The company focuses on developing sustainable biotechnology solutions to address chronic and acute respiratory conditions, particularly COPD. Their innovative inhaled therapy, MA001, aims to reduce lung inflammation and viral infections, potentially preventing exacerbations and disease progression. MicroA is committed to sustainable production, leveraging industrial fermentation technology to contribute to a blue-green bioeconomy and support global health goals. The company collaborates with leading organizations and has a highly experienced team dedicated to improving patient outcomes through groundbreaking technologies.
Industries
Nr. of Employees
small (1-50)
MicroA
Patents
Products
Inhaled sulphated polysaccharide therapeutic (clinical candidate)
A preclinical inhaled therapeutic candidate derived from sulphated polysaccharides designed to provide combined local antiviral and anti-inflammatory effects in the lung to reduce exacerbations in chronic respiratory disease.
Inhaled sulphated polysaccharide therapeutic (clinical candidate)
A preclinical inhaled therapeutic candidate derived from sulphated polysaccharides designed to provide combined local antiviral and anti-inflammatory effects in the lung to reduce exacerbations in chronic respiratory disease.
Services
Research collaborations with academic and government institutes and contract research organisations to advance preclinical development of respiratory therapeutics.
In-house production capabilities for fermentation-derived therapeutic ingredients with a sustainability focus and ability to scale processes.
Fundraising, investor engagement and licensing strategy to progress therapeutic candidates toward market via partnerships or licensing.
Research collaborations with academic and government institutes and contract research organisations to advance preclinical development of respiratory therapeutics.
In-house production capabilities for fermentation-derived therapeutic ingredients with a sustainability focus and ability to scale processes.
Fundraising, investor engagement and licensing strategy to progress therapeutic candidates toward market via partnerships or licensing.
Expertise Areas
- Respiratory therapeutics (COPD‑focused)
- Bioprocessing and industrial fermentation
- Natural polysaccharide discovery and development
- Preclinical pharmacology and in vivo efficacy testing
Key Technologies
- Industrial fermentation
- Inhaled drug delivery
- Sulfated polysaccharide therapeutics
- Preclinical animal models